ACADIA’s $1B+ 2025 revenue outlook is driven by NUPLAZID and DAYBUE, with ACP-101 offering optional upside despite risks.

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $29.06, along ...

What happenedShares of Acadia Pharmaceuticals (NASDAQ: ACAD) were soaring 18.3% higher as of 11:03 a.m. ET on Friday. The big jump came after the drugmaker announced on Thursday that it has ...

Revenue Growth: ACADIA Pharmaceuticals's remarkable performance in 3 months is evident. As of 31 March, 2024, the company achieved an impressive revenue growth rate of 73.75%.

Acadia Pharmaceuticals (NASDAQ: ACAD) is probably in better shape now than it's ever been. The biotech won approval last year for its lead product, Nuplazid, in treating Parkinson's disease psychosis.

In the assessment of 12-month price targets, analysts unveil insights for ACADIA Pharmaceuticals, presenting an average target of $33.37, a high estimate of $42.00, and a low estimate of $19.00.

Acknowledging the limits of disease-modifying drugs like Leqembi and Kisunla, companies like Bristol Myers Squibb, Acadia, ...

ACADIA Pharmaceuticals Inc has a consensus price target of $28.54 based on the ratings of 25 analysts. The high is $42 issued by Cantor Fitzgerald on August 22, 2023.

Acadia Pharmaceuticals (ACAD 14.48%) is having a strong session Tuesday. Specifically, the drugmaker's shares were up by a healthy 6.7% on moderate volume at 10:02 a.m. ET.

ACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS ...

Acadia's surprise Nuplazid snag—and subsequent cold shoulder at FDA—beg more questions than answers By Beth Snyder Bulik Mar 9, 2021 12:37pm dementia drug labels Acadia Pharmaceuticals Nuplazid ...

Acadia Pharmaceuticals's first-quarter sales were driven by strong execution in marketing and commercial strategy. The $90.1 million in revenue came from 32% volume growth year over year.